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ORIGINAL INVESTIGATION
Upregulation of inducible NO synthase 
by exogenous adenosine in vascular smooth 
muscle cells activated by inflammatory stimuli 
in experimental diabetes
Alberto Nassi1,3, Francesca Malorgio1, Serena Tedesco1, Andrea Cignarella2*†  and Rosa Maria Gaion1†
Abstract 
Background: Adenosine has been shown to induce nitric oxide (NO) production via inducible NO synthase (iNOS) 
activation in vascular smooth muscle cells (VSMCs). Although this is interpreted as a beneficial vasodilating pathway 
in vaso-occlusive disorders, iNOS is also involved in diabetic vascular dysfunction. Because the turnover of and the 
potential to modulate iNOS by adenosine in experimental diabetes have not been explored, we hypothesized that 
both the adenosine system and control of iNOS function are impaired in VSMCs from streptozotocin-diabetic rats.
Methods: Male Sprague–Dawley rats were injected with streptozotocin once to induce diabetes. Aortic VSMCs from 
diabetic and nondiabetic rats were isolated, cultured and exposed to lipopolysaccharide (LPS) plus a cytokine mix 
for 24 h in the presence or absence of (1) exogenous adenosine and related compounds, and/or (2) pharmacologi-
cal agents affecting adenosine turnover. iNOS functional expression was determined by immunoblotting and NO 
metabolite assays. Concentrations of adenosine, related compounds and metabolites thereof were assayed by HPLC. 
Vasomotor responses to adenosine were determined in endothelium-deprived aortic rings.
Results: Treatment with adenosine-degrading enzymes or receptor antagonists increased iNOS formation in acti-
vated VSMCs from nondiabetic and diabetic rats. Following treatment with the adenosine transport inhibitor NBTI, 
iNOS levels increased in nondiabetic but decreased in diabetic VSMCs. The amount of secreted NO metabolites was 
uncoupled from iNOS levels in diabetic VSMCs. Addition of high concentrations of adenosine and its precursors or 
analogues enhanced iNOS formation solely in diabetic VSMCs. Exogenous adenosine and AMP were completely 
removed from the culture medium and converted into metabolites. A tendency towards elevated inosine generation 
was observed in diabetic VSMCs, which were also less sensitive to CD73 inhibition, but inosine supplementation did 
not affect iNOS levels. Pharmacological inhibition of NOS abolished adenosine-induced vasorelaxation in aortic tis-
sues from diabetic but not nondiabetic animals.
Conclusions: Endogenous adenosine prevented cytokine- and LPS-induced iNOS activation in VSMCs. By contrast, 
supplementation with adenosine and its precursors or analogues enhanced iNOS levels in diabetic VSMCs. This effect 
was associated with alterations in exogenous adenosine turnover. Thus, overactivation of the adenosine system may 
foster iNOS-mediated diabetic vascular dysfunction.
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Background
The pathophysiology of vascular disease associated with 
diabetes mellitus involves abnormalities in the functions 
of resident and circulating cells [1] as well as low-grade 
vascular inflammation with increased cytokine release. 
Diabetes is associated with altered expression and func-
tion of adenosine receptors, which are expressed on most 
cell types in the cardiovascular system [2]. Increased 
activity of the adenosine-degrading enzyme adenosine 
deaminase (ADA) has been also reported in diabetic 
patients [3] and experimental animals [4], suggesting 
that alterations in the adenosine system contribute to the 
pathophysiology of the disease.
Vascular smooth muscle cells (VSMCs) have an active 
adenosine metabolism [5, 6], and express all known 
adenosine receptors [7]. Under conditions such as 
hypoxia, ischaemia or inflammation, the level of extracel-
lular adenosine increases dramatically to improve blood 
flow via vasodilator A2A and A2B receptors expressed 
on the endothelium and smooth muscle [8]. Adeno-
sine that accumulates in the extracellular compartment, 
thus reaching its cell surface receptors, can be released 
as such by means of bidirectional equilibrative nucleo-
side transporters (ENTs), or formed extracellularly from 
cell-derived nucleotides that are dephosphorylated by 
enzymes bound to the external surface of plasma mem-
brane. Among these, ecto-5′ nucleotidase (CD73) pro-
motes the final conversion of AMP into adenosine. On 
the other hand, metabolic conversion by ecto-ADA and 
transport into cells mediated by ENTs and/or concen-
trative nucleoside transporters account for adenosine 
removal from the extracellular space [9, 10]. In VSMCs, 
95  % of adenosine transport is mediated by ENT-1 and 
the rest by ENT-2 [10].
Sustained production of nitric oxide (NO) through the 
inducible form of NO synthase (iNOS) is a response to 
a variety of agents including proinflammatory cytokines 
[11]. VSMCs are endowed with the metabolic machinery 
that allows release of large amounts of NO in response 
to cytokines and endotoxin [12–16]. The ability of aden-
osine to increase basal as well as cytokine- or lipopoly-
saccharide (LPS)-stimulated NO release in VSMCs is 
documented [17–19], and it is interpreted as a potential 
beneficial effect, inasmuch as it would prevent patho-
logic vaso-occlusion triggered by other local mediators 
[20, 21]. On the other hand, the augmented release of NO 
derived from iNOS is involved in the development of dia-
betic vascular complications [22–24].
We therefore hypothesized that experimental type I 
diabetes would alter the modulation of iNOS protein 
synthesis and activity by exogenous adenosine and agents 
affecting its turnover in VSMCs. We tested this hypoth-
esis by isolating VSMCs from aortas of diabetic and 
nondiabetic rats, stimulating VSMCs with LPS combined 
with a cytokine cocktail in the presence or absence of 
adenosine and related compounds, and assessing iNOS 
functional expression as well as adenosine turnover. Our 
results indicated that, while endogenous adenosine atten-
uated iNOS production, supplementation with exog-
enous adenosine was associated with abnormal purine 
turnover and enhanced iNOS levels in diabetic VSMCs, 
which may foster diabetic vascular dysfunction.
Methods
Chemicals and antibodies
Streptozotocin (STZ) and MRS 1730 were purchased 
from Tocris Cookson. The anti-iNOS antibody was from 
BD Biosciences, whereas the peroxidase-coupled sec-
ondary antibody was obtained from Vector. Recombi-
nant rat cytokines were obtained from Tebu-Bio. Unless 
otherwise specified, chemicals were purchased from 
Sigma-Aldrich.
Animals
Male Sprague-Dawley rats weighing 200–250 g (Charles 
River, Italy) were kept in temperature-controlled facilities 
on a 12-hour light-dark cycle and fed normal chow. At 
the time of cell or tissue harvest, animals were sacrificed 
by asphyxia using carbon dioxide. The work described 
has been carried out in accordance with the EU Directive 
2010/63/EU for animal experiments (http://ec.europa.eu/
environment/chemicals/lab_animals/legislation_en.htm).
Diabetes induction
Diabetes was induced by a single i.p. injection of 65 mg/
Kg STZ freshly dissolved in 50  mM citrate buffer (pH 
4.5). Blood glucose was monitored weekly after STZ 
injection using Glucurtest (Roche Diagnostics). Animals 
were diabetic for 3 weeks prior to aortic harvest and vas-
cular cell isolation. Only hyperglycemic rats with fasting 
blood glucose ≥11.1 mM were selected for experiments.
Cell culture
VSMCs from aortic intimal-medial layers were isolated 
and cultured as previously described [15, 25]. Briefly, 
VSMCs were synchronized in medium containing 0.4 % 
FCS for 24  h and incubated for a further 24  h where 
indicated with a cytokine mixture comprising 10 ng/mL 
interleukin (IL)-1β, 10  ng/mL interferon (IFN)-γ and 
25  ng/mL tumor necrosis factor (TNF)-α plus 1  µg/mL 
LPS. Such a mixture consistently induces iNOS protein 
formation in VSMCs [25].
Western blotting
Cultured VSMCs were washed twice with phosphate-
buffered saline and extracted directly into lysis buffer 
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as described elsewhere [26]. At least 30  µg cell protein 
were loaded onto 10  % SDS-acrylamide gels. Following 
electrophoresis, proteins were transferred onto Hybond-
ECL membranes (GE Healthcare), which were incu-
bated in blocking solution for 2 h and then with primary 
antibodies (1:1000) overnight at RT. After washing, the 
peroxidase-conjugated secondary antibody (1:1000) was 
applied for 1 h at RT. After extensive washing, the blots 
were developed using an enhanced chemiluminescence 
kit (GE Healthcare). Sample loading control was per-
formed through β-actin immunodetection. The values of 
iNOS protein were normalized to those of β-actin.
Nitrite assay
The culture medium was collected and centrifuged at 
12,000 rpm for 5 min. Next, 250 µL/well of medium were 
treated with 20 µl of 6.5 M HCl and 20 µl of 37.5 mM sul-
fanilic acid in a 96-well plate. After incubation for 10 min, 
20 µL of 12.5  mM  N-(1-naphthyl)-ethylendiamine was 
added. Optical density was read at 550 nm after 15 min. 
Nitrite values were expressed as µmol  nitrite/mg cell 
protein.
Analyses of purine substrates and metabolites
Adenosine and its metabolites in VSMC culture medium 
were separated by high-performance liquid chromatogra-
phy (HPLC) and quantified by UV absorption at 254 nm 
as previously described [27]. Briefly, medium samples 
were neutralized to a pH of 4–5 and mixed with 50 µM 
theophylline as internal standard. After centrifugation, 
supernatants were filtered through a 0.22  µm syringe 
filter. HPLC separation was achieved with a Beckman 
System Gold Programmable Solvent Module 125 on a 
Beckman C18 Analytical Ultrasphere column coupled to 
a Beckman Detector 166, using a non-linear NaH2PO4/
tetrabutylammonium bromide (73.5/6  mM, pH 
5.8)-methanol (0–25  %) gradient over 38  min, at a flow 
rate of 1 ml/min. The concentration of adenosine and its 
metabolites were extrapolated from calibration curves 
constructed through multiple determinations of standard 
amounts by plotting the peak areas against the concen-
tration of the sample. Linearity of the assay was assessed 
using three calibration curves analyzed on separate days. 
The limit of detection and the lower limit of quantifica-
tion were above 0.1 and 0.5 μM, respectively.
Vascular reactivity
Changes in vasomotor tone of aortic tissues in response 
to adenosine were recorded in organ chambers. The tho-
racic aorta was carefully removed, cleaned of fat and con-
nective tissue, and cut into 5–6  mm rings. Rings were 
suspended in Krebs-Henselheit solution with the follow-
ing composition (mM): NaCl 118, KCl 4.7, KH2PO4 1.2, 
MgSO4 1.1, CaCl2 2.5, NaHCO3 25 and glucose 5.5; pH 
7.4, maintained at 37  °C and continuously aerated with 
95 % O2, 5 % CO2 for isometric tension recording in organ 
chambers. In some rings, endothelium was mechanically 
removed. The rings were connected to isometric ten-
sion transducers (Fort 10, World Precision Instruments) 
coupled with a digital recording system (PowerLab 8SP, 
ADInstruments). The completeness of endothelial denu-
dation was confirmed by the absence of relaxation to 
the endothelial-dependent agonist acetylcholine (1 µM). 
After a 90-min equilibration period under a resting ten-
sion of 2  g, rings were constricted with 0.1  µM norepi-
nephrine, and vasorelaxant responses to adenosine were 
determined in endothelium-denuded rings. When indi-
cated, rings were previously incubated for 60 min either 
with vehicle (control) or the NO synthase inhibitor NG-
monomethyl-l-arginine (L-NMA; 10 µM).
Statistical analysis
Data are expressed as mean  ±  SEM, or as percentage, 
where appropriate. Comparison between 2 or more 
groups was performed using the Student’s t test and 
ANOVA, respectively. Linear correlations were checked 
using the Pearson’s r coefficient. Statistical analysis was 
accepted at P < 0.05 and SPSS ver. 21.0 was used.
Results
Influence of endogenous adenosine on iNOS 
synthesis and activity in VSMCs from diabetic rats 
and normoglycemic controls
We previously reported that iNOS expression and release 
of NO metabolites in response to 24-h stimulation with 
LPS and cytokines are attenuated by about 30 % in cul-
tured VSMCs from STZ-diabetic rats as compared to 
those from normoglycemic rats [15, 28]. In the absence 
of inflammatory stimuli, iNOS is undetectable in these 
cells [15, 28]. This pattern was confirmed in the present 
study. In fact, at the end of a 24-h incubation of control 
or diabetic VSMCs in the presence of LPS and cytokines, 
which reproduce a setting of vascular inflammation, 
iNOS became detectable by Western blot (Fig. 1). Treat-
ment with ADA to remove endogenous adenosine from 
the incubation medium enhanced the iNOS response 
to LPS/cytokines in both control and diabetic VSMCs. 
This effect was mimicked by the nonselective adenosine 
receptor antagonist 8-phenyltheophylline (8-PT; Fig. 1a, 
b).
In stimulated VSMCs from nondiabetic rats, the 
adenosine deaminase inhibitor erythro-9-(2-Hydroxy-3-
nonyl)adenine (EHNA) reduced iNOS synthesis while the 
ENT inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBTI) 
enhanced it, and the CD73 inhibitor α,β-Methylene-
ADP (AOPCP) was ineffective (Fig. 2a). In VSMCs from 
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diabetic rats, under the same experimental conditions, 
EHNA did not cause any significant change in iNOS pro-
tein level. In contrast, AOPCP and NBTI partially pre-
vented iNOS formation (Fig. 2b).
In the above experiments, measurement of NO metab-
olites’ accumulation in the culture medium showed a 
direct and significant correlation between iNOS protein 
levels and enzyme activity in control VSMCs, which was 
disrupted in diabetic VSMCs (Fig. 3).
Influence of exogenous adenosine on iNOS production
Under stimulation with LPS/cytokines, addition of aden-
osine did not alter iNOS levels in control VSMCs, while a 
significant 60 % increase was observed in diabetic VSMCs 
at the highest concentration tested (Table 1). In the pres-
ence of exogenous adenosine, iNOS protein levels were 
not affected by addition of EHNA or NBTI. Similarly, 
AOPCP did not alter the iNOS response to exogenous 
AMP (Table  1). Pretreatment of diabetic VSMCs with 
MRS1706 (0.1 μM, A2B selective antagonist) significantly 
decreased adenosine-induced iNOS accumulation, in line 
with previous reports showing a prominent role for the 
A2B receptor pathway [18, 19].
In these experiments the nucleoside measured in 
the medium after incubation was in the submicromo-
lar range, often below the detection limit of our HPLC 
method (Fig.  4). When adenosine was measured imme-
diately after its addition to the incubation medium 
(time zero, not shown), its recovery was close to 100  % 
(e.g. 99 ± 2 µM and 99 ± 1 µM in control and diabetic 
VSMCs, respectively, for 100 µM adenosine, n = 3).
Similar to 100 µM adenosine, the ADA-resistant aden-
osine derivative, phenylisopropyladenosine (PIA), as well 
as the direct precursor AMP increased iNOS protein 
level in diabetic VSMCs but were ineffective in those 
from control animals (Fig.  5). The deamination product 
of adenosine, inosine, did not alter iNOS levels in either 
cell type (Fig. 5).
Turnover of exogenous adenosine
Cultured VSMCs release purine and pyrimidine nucleo-
sides and their metabolites into external medium under 
basal conditions [5]. In the medium of VSMCs incu-
bated for 24  h with or without LPS/cytokines, the only 
detectable metabolite was hypoxanthine: 14.2 ± 1.4 and 
12.0 ± 3.6 µM, respectively, in control VSMCs; 11.7 ± 1.9 
Fig. 1 Immunoblots for iNOS in VSMCs from control (a) and STZ-diabetic rats (b) in the presence of endogenous adenosine modulators. VSMCs 
were incubated with cytomix comprising 10 ng/mL interleukin (IL)-1β, 10 ng/mL interferon (IFN)-γ and 25 ng/mL tumor necrosis factor (TNF)-α plus 
1 µg/mL LPS for 24 h. Representative blots are shown. Densitometric analysis of iNOS protein levels are shown as % cytomix. The data are presented 
as mean ± SEM (n = 8). *P < 0.05, **P < 0.01 (two-tailed t-test). ADA, adenosine deaminase; 8-PT, 8-phenyltheophylline
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Fig. 2 Immunoblots for iNOS in VSMCs from control (a) and STZ-diabetic rats (b) in the presence of adenosine turnover modulators. VSMCs were 
incubated as described in the legend to Fig. 1. Representative blots are shown. Densitometric analysis of iNOS protein levels are shown as  % cyto-
mix. The data are presented as mean ± SEM (n = 8). *P < 0.05 (two-tailed t-test). NBTI, S-(4-Nitrobenzyl)-6-thioinosine; EHNA, erythro-9-(2-Hydroxy-3-
nonyl)adenine; AOPCP, α,β-Methylene-ADP
Fig. 3 Correlations between iNOS levels and NO metabolite release into the culture medium of VSMCs from control (a) and STZ-diabetic rats (b). 
iNOS level data are from experiments shown in Figs. 1 and 2
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and 10.8  ±  2.1  µM, respectively, in diabetic VSMCs 
(n = 4).
As observed with adenosine (Fig.  4), AMP was effi-
ciently cleared from the medium: both AMP and aden-
osine were undetectable after 24  h (Fig.  6). By contrast, 
exogenous inosine was only partially removed as its 
concentration accounted for more than 25  % of the 
nucleoside added at the beginning of the experiments 
in nondiabetic VSMCs, and this fraction increased to 
almost 45  % in diabetes (Fig.  6). Interestingly, for both 
cell types, these inosine concentrations were not signifi-
cantly different from those recovered upon incubation 
with adenosine but were higher than those resulting from 
AMP degradation (Fig. 6). Adenosine, AMP and inosine 
were further converted into hypoxanthine, whose accu-
mulation equalled 48–51 % of added substrates in control 
VSMCs. In diabetic VSMCs this fraction was comparable 
when adding AMP as a substrate, but decreased to less 
than 30 % when cells were incubated with adenosine or 
inosine (Fig.  6). The same incubations were performed 
also in the absence of cells, in order to detect spontane-
ous degradation and/or identify any bias related to pos-
sible ADA, 5′-nucleotidase and/or purine nucleoside 
phosphorylase (PNP) activity associated with FCS in the 
culture medium. Indeed, detectable amounts of inosine 
were also measured in samples incubated with AMP or 
adenosine. About half of exogenous AMP was converted 
to adenosine, while hypoxanthine concentrations did 
not differ from baseline levels (Fig.  6c). Treatment with 
pharmacological inhibitors did not enhance endogenous 
adenosine or AMP to detectable levels (data not shown).
In the presence of exogenous adenosine, EHNA and, 
to a lesser extent, NBTI reduced the purine clearance, 
allowing its partial recovery in the medium, which was 
quantitatively similar for diabetic and control VSMCs 
(Fig.  7). By contrast, in those samples in which AMP 
was combined with AOPCP, the amount of recovered 
AMP accounted for half of the nucleotide added to con-
trol VSMCs, but for less than 10 % in experiments with 
Table 1 Effects of exogenous adenosine/AMP on cytokine-
induced iNOS synthesis in aortic smooth muscle cells
Rat aortic smooth muscle cells from control and diabetic rats were incubated 
with 10 ng/mL interleukin (IL)-1β, 10 ng/mL interferon (IFN)-γ and 25 ng/mL 
tumor necrosis factor (TNF)-α plus 1 µg/mL LPS for 24 h. iNOS was detected by 
Western blot. Densitometric analysis of protein level is expressed as % of No 
addition
EHNA erythro-9-(2-Hydroxy-3-nonyl)adenine, NBTI S-(4-Nitrobenzyl)-6-
thioinosine, AOPCP α,β-Methylene-ADP
* P < 0.01 vs. No addition, ** P < 0.05 vs. Adenosine 100 µM (two-tailed t test)
a n = 3
Relative densitometric analysis 
of iNOS levels (arbitrary units)
Control (n = 7) Diabetes (n = 8)
No addition 100 ± 8 100 ± 12
Adenosine 1 µM 95 ± 12 91 ± 7
Adenosine 10 µM 90 ± 12 114 ± 7
Adenosine 100 µM 97 ± 9 161 ± 14*
Adenosine 100 µM + EHNA 1 µM 112 ± 10 152 ± 14*
Adenosine 100 µM + NBTI 10 µM 93 ± 10 154 ± 22*
Adenosine 100 µM + MRS1706  
1 µMa
90 ± 15 108 ± 11**
AMP 100 µM 108 ± 6 150 ± 12*
AMP 100 µM + AOPCP 200 µM 115 ± 9 176 ± 19*
Fig. 4 Residual adenosine concentration as measured by HPLC in the culture medium of VSMCs from control (a) and STZ-diabetic rats (b) following 
incubation with increasing adenosine concentrations (1–100 µM) for 24 h. The values represent the mean ± SEM (n = 10)
Page 7 of 11Nassi et al. Cardiovasc Diabetol  (2016) 15:32 
Fig. 5 Immunoblots for iNOS in VSMCs from control (a) and STZ-diabetic rats (b) in the presence of exogenous purines. VSMCs were incubated as 
described in the legend to Fig. 1. Representative blots are shown. Densitometric analysis of iNOS protein levels are shown as % cytomix. The values 
represent the mean ± SEM (n = 5). *P < 0.05 (two-tailed t-test). PIA, N-(2-phenylisopropyl)-adenosine
Fig. 6 Residual concentration of adenosine and its metabolites as measured by HPLC following incubation with adenosine, AMP or inosine (all 
100 µM) for 24 h in cell-free culture medium (a) or the culture medium of VSMCs from control (b) and STZ-diabetic rats (c). The values represent the 
mean ± SEM (n = 10)
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diabetic VSMCs (Fig.  7), indicating that diabetes mark-
edly reduced CD73 sensitivity to pharmacological inhibi-
tion by AOPCP.
Adenosine‑induced relaxation of endothelium‑denuded 
aortic rings
In order to access a possible role of smooth muscle NOS 
in the vasorelaxant effect of adenosine, ex  vivo experi-
ments were performed on rings of endothelium-denuded 
rat aorta pre-contracted with norepinephrine. Under 
these conditions acetylcholine barely affected vascular 
tone (−10.5 ± 2.4, and −11.2 ± 4.9 %, change in norep-
inephrine-induced tension in preparations from control 
and diabetic rats, respectively; NS, n = 3), while adenosine 
significantly relaxed vascular tissues by up to 25.1 ±  5.4 
and 35.3  ±  4.6  % in diabetic and control preparations, 
respectively (Fig.  8). Interestingly, pre-treatment with 
L-NMA abolished the vasorelaxant effect of adenosine in 
diabetic but not in nondiabetic aortic tissues (Fig. 8).
Discussion
Diabetes affects the modulation of VSMC function 
by adenosine. For instance, primary cultures of aortic 
VSMCs obtained from rats with streptozotocin-induced 
diabetes mellitus have a greater susceptibility to the 
inhibitory effects of adenosine on cell proliferation [29]. 
Our results showed alterations in adenosine turnover 
and modulation of iNOS synthesis in the same cell model 
that can be relevant in the setting of diabetic vascular 
dysfunction.
Fig. 7 Residual concentration of adenosine, AMP and metabolites thereof as measured by HPLC following incubation with adenosine or AMP (both 
100 µM) for 24 h in the culture medium of VSMCs from control (a) and STZ-diabetic rats (b). Inhibitors of adenosine/AMP turnover were added as 
indicated. The values represent the mean ± SEM (n = 6). NBTI, S-(4-Nitrobenzyl)-6-thioinosine; EHNA, erythro-9-(2-Hydroxy-3-nonyl)adenine; AOPCP, 
α,β-methylene-ADP
Fig. 8 Concentration-response curves of endothelium-deprived 
aortic rings from control and STZ-diabetic rats precontracted with 
0.1 µM noradrenaline and incubated with increasing concentrations 
of adenosine in the presence or absence of the NO synthase inhibitor 
L-NMA (10 µM). n = 5–7. Diabetes + NMA vs. diabetes, P < 0.001 
(two-way ANOVA). Control vs. diabetes and control + NMA vs. con-
trol, ns not significant
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Regulation of iNOS functional expression by endogenous 
vs. exogenous adenosine
We found that endogenous adenosine impairs LPS/
cytokine-induced iNOS formation in VSMCs, as shown 
by iNOS upregulation following treatment with ADA 
and with the nonspecific adenosine receptor antago-
nist 8-PT. Similarly, the ENT1 inhibitor NBTI enhanced 
iNOS accumulation in control VSMCs, in line with the 
observation that the adenosine uptake inhibitor dipyrida-
mole up-regulates the IL-1β–induced NO production 
in a dose-dependent manner [30]. Under inflammatory 
conditions adenosine was released through ENTs in con-
trol VSMCs, whereas the transport direction appeared to 
be reversed in diabetic VSMCs. It has been speculated 
that increased ENT-1 activity as described in  vitro in 
human SMCs exposed to hyperglycemia [31] or isolated 
from diabetic patients [32] may reduce adenosine avail-
ability to its receptors, thereby weakening the vascular 
functions of adenosine [10]. In diabetes, ENT-mediated 
transport is the main mechanism that cleared extracel-
lular adenosine, while under control conditions ADA 
played a greater functional role. In the presence of the 
5′-ectonucleotidase inhibitor AOPCP, extracellular AMP 
could achieve concentrations that mimicked the effects of 
adenosine on iNOS.
In contrast to previous reports [17–19], we were unable 
to detect increased iNOS functional expression by exog-
enous adenosine in VSMC from normoglycemic rats. 
Because either LPS or IL-1β alone were used to activate 
VSMCs in those studies, it is conceivable that the LPS/
cytokine cocktail as used in the present study induced 
maximal iNOS activation via cyclic AMP [13] that could 
not be further enhanced by adenosine as described in 
the above-mentioned studies. However, we found that 
diabetes enhanced VSMC sensitivity to high concentra-
tions of exogenous adenosine in terms of LPS/cytokine-
induced iNOS production. To the best of our knowledge 
this finding is novel, and was likely determined by func-
tional abnormality in Gi activity as described previously 
in VSMCs from diabetic rats [29] or activation of second 
messengers other than cAMP by high adenosine con-
centrations as suggested by others [17]. Because stimu-
lated diabetic rat-derived VSMCs express less iNOS than 
control VSMC at earlier time points [15, 28] (Fig. 1), the 
increase in iNOS seen with 100 µM adenosine (Table 1) 
may be viewed as a short-term compensatory and ben-
eficial effect. Whether exogenous adenosine affects the 
delayed response to long-term cytokine stimulation 
previously reported to occur in diabetic VSMCs [15] 
requires further investigation.
Unlike in control VSMCs, iNOS formation and NO 
release were found to be uncoupled in VSMCs from dia-
betic rats. Post-translational iNOS regulation may occur 
via several mechanisms including homodimerization by 
NOS-associated protein 1.10 kd (NAP110; [33]) or spe-
cific trafficking and activity regulation by multifunctional 
Ca2+/calmodulin-dependent protein kinase II (CaM-
KII; [34]). As the latter mechanism has been shown to 
be upregulated in VSMCs from diabetic rats [24], the 
observed uncoupling may be due to enhanced intracel-
lular nitrotyrosine generation that is undetectable in the 
culture medium. This may represent a mechanism of cell/
tissue injury involved in diabetic vascular dysfunction.
Functional implications of perturbed NO levels in diabetes
Attenuated adenosine-mediated endothelium-dependent 
vasodilatation has been demonstrated in diabetic patients 
[35]. In agreement with previous studies [36], however, 
we found no abnormality in the relaxant response to 
adenosine of endothelium-denuded aortic rings due to 
diabetes. Our experiments in aortic rings not exposed 
to exogenous inflammatory stimuli (Fig.  8) suggest that 
smooth muscle NOS contributed significantly to adeno-
sine-mediated vasorelaxation in vessels from diabetic but 
not nondiabetic rats, most likely due to increased iNOS 
expression in diabetic vessels [37, 38].
It should be pointed out that activation of NO synthase 
in diabetes is a multifactorial issue. For instance, overex-
pression of SIRT1 reduces diabetes-exacerbated myocar-
dial ischemia-reperfusion injury and oxidative stress via 
activating eNOS in diabetic rats [39], and the vasculopro-
tective effect of insulin after arterial injury is mediated 
by an eNOS-dependent mechanism [40]. On the other 
hand, excess NO impairs glycemic control by diminish-
ing insulin-stimulated muscle glucose uptake [41]. People 
with diabetes tend to have lower global levels of NO [42]. 
Therefore, beyond contributing to the homeostasis of the 
vasculature, NO is a key signaling molecule for insulin 
action and glucose disposal.
Adenosine metabolism and turnover are altered in diabetic 
rat‑derived VSMCs
With regard to major purine-inactivating pathways, 
ADA and CD73 were remarkably active in both control 
and diabetic VSMCs, with no residual AMP or adeno-
sine found in the medium 24  h after supplementation. 
We also found a tendency to increased inosine genera-
tion following adenosine supplementation by diabetic 
VSMCs, possibly as a result of increased ADA activity, as 
described in diabetic patients [43] and in experimental 
models of hypertension [44]. Residual inosine concen-
trations following inosine supplementation to diabetic 
VSMCs were also higher than in control VSMCs. Thus, 
the enzyme PNP, which generates hypoxanthine from 
inosine, appeared to be the rate limiting step in adeno-
sine catabolism, with somewhat lower activity in diabetic 
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compared with control VSMCs. Yet supplementation of 
inosine, unlike that of adenosine, had no effect on iNOS 
synthesis in diabetic VSMCs. Overall, these findings 
point to alterations in the degradation pathways of exog-
enous purines in diabetes, which may have functional 
implications in VSMC function.
Conclusions
To sum up, iNOS production induced by inflamma-
tory stimuli was attenuated by endogenous adenosine 
in VSMCs, whereas addition of high concentrations of 
adenosine and its precursors/analogues enhanced iNOS 
production in diabetic compared with nondiabetic 
VSMCs. While it may be viewed as a compensatory and 
beneficial effect, the increase in iNOS mediated by exog-
enous adenosine was associated with abnormal purine 
turnover. Hence, NO-related alterations in adenosine 
metabolism and anti-inflammatory pathways may be 
involved in diabetic vascular dysfunction.
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